摘要:
The invention relates to a method for the production of a compound of general formula (Ia), wherein X represents a halogen atom or a pharmaceutically acceptable salt thereof, wherein a compound of formula (II), in which X is defined as above and Y and Z represent a leaving independently of one another, is reacted with an optically active amino alcohol in order to obtain a first mixture of diastereomers.
摘要:
The invention provides a process for the preparation of the polymorph from I of agomelatine, characterized by the following crystal data: C 15 H 17 N0 2 Mr = 243.30 Orthorhombic Pca2 1 a = 31.501 (4) Å b = 9.5280 (10) Å c = 17.906 (2) Å Z = 16 the process comprising the process steps of: a) dissolving agomelatine in a solvent to obtain a solution, b) adding the solution to an organic anti-solvent having a temperature of 30°C or below, whereby crystals of the polymorph form I of agomelatine are formed, wherein the solvent of step a) is miscible with the anti-solvent of step b), c) isolating the crystals of the polymorph form I of agomelatine and d) optionally drying the isolated crystals of the polymorph form I of agomelatine.
摘要:
The present invention relates to a pharmaceutical composition comprising N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide as active pharmaceutical ingredient.
摘要:
The present invention relates to a pharmaceutical composition comprising N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide as active pharmaceutical ingredient.
摘要:
The invention relates to a method for the production of a compound of general formula (Ia), wherein X represents a halogen atom or a pharmaceutically acceptable salt thereof, wherein a compound of formula (II), in which X is defined as above and Y and Z represent a leaving independently of one another, is reacted with an optically active amino alcohol in order to obtain a first mixture of diastereomers.